advertisement

---

Siesky B 11

Showing records 1 to 11 | Display all abstracts from Siesky B

95853 Topical carbonic anhydrase inhibitors and glaucoma in 2021: where do we stand?
Stoner A
British Journal of Ophthalmology 2022; 106: 1332-1337

---

95967 Prevalence Rates and Risk Factors for Primary Open Angle Glaucoma in the Middle East
Torabi R
Journal of ophthalmic & vision research 2021; 16: 644-656

---

95853 Topical carbonic anhydrase inhibitors and glaucoma in 2021: where do we stand?
Harris A
British Journal of Ophthalmology 2022; 106: 1332-1337

---

95967 Prevalence Rates and Risk Factors for Primary Open Angle Glaucoma in the Middle East
Harris A; Siesky B
Journal of ophthalmic & vision research 2021; 16: 644-656

---

95853 Topical carbonic anhydrase inhibitors and glaucoma in 2021: where do we stand?
Oddone F; Belamkar A
British Journal of Ophthalmology 2022; 106: 1332-1337

---

95967 Prevalence Rates and Risk Factors for Primary Open Angle Glaucoma in the Middle East
Zukerman R; Oddone F
Journal of ophthalmic & vision research 2021; 16: 644-656

---

95853 Topical carbonic anhydrase inhibitors and glaucoma in 2021: where do we stand?
Verticchio Vercellin AC; Shin J
British Journal of Ophthalmology 2022; 106: 1332-1337

---

95967 Prevalence Rates and Risk Factors for Primary Open Angle Glaucoma in the Middle East
Mathew S
Journal of ophthalmic & vision research 2021; 16: 644-656

---

95853 Topical carbonic anhydrase inhibitors and glaucoma in 2021: where do we stand?
Januleviciene I
British Journal of Ophthalmology 2022; 106: 1332-1337

---

95967 Prevalence Rates and Risk Factors for Primary Open Angle Glaucoma in the Middle East
Januleviciene I; Vercellin ACV
Journal of ophthalmic & vision research 2021; 16: 644-656

---

95853 Topical carbonic anhydrase inhibitors and glaucoma in 2021: where do we stand?
Siesky B
British Journal of Ophthalmology 2022; 106: 1332-1337

---